PCH vs PNH: Key Differences

Paroxysmal cold hemoglobinuria (PCH) and paroxysmal nocturnal hemoglobinuria (PNH) are fundamentally distinct hemolytic disorders that differ completely in their underlying mechanisms, with PCH being an autoimmune disease triggered by cold exposure and PNH being a clonal stem cell disorder with complement dysregulation.

Pathophysiology

PCH (Paroxysmal Cold Hemoglobinuria)

Autoimmune mechanism: Caused by the Donath-Landsteiner (DL) antibody, a biphasic IgG autoantibody that binds to red blood cells at cold temperatures and causes complement-mediated hemolysis upon rewarming 1.
Complement activation: The DL antibody fixes complement at cold temperatures, leading to intravascular hemolysis when blood returns to warmer body temperature 1.
Non-clonal disorder: Does not involve stem cell mutations or clonal expansion 1.

PNH (Paroxysmal Nocturnal Hemoglobinuria)

Clonal stem cell disorder: Results from somatic mutations in the X-linked PIGA gene in hematopoietic stem cells, leading to deficiency of glycosylphosphatidylinositol (GPI)-anchored proteins 2, 3.
Loss of complement regulation: Absence of CD55 and CD59 (GPI-anchored complement regulatory proteins) causes uncontrolled complement activation on red blood cells 4, 5.
Clonal expansion mechanism: The mutant clone expands, likely through immune escape from T-cell-mediated autoimmune attack on normal stem cells 2.
Three-component pathogenesis: Intravascular hemolysis, thrombophilia, and bone marrow failure 6, 3.

Clinical Presentation

PCH

Cold-triggered hemolysis: Hemolytic episodes occur after cold exposure, with symptoms including dark urine, fever, back pain, and abdominal pain 1.
Episodic nature: Attacks are paroxysmal and related to cold exposure rather than continuous 1.
Often post-infectious: Frequently occurs following viral infections, particularly in children 1.
No thrombotic risk: Unlike PNH, PCH does not carry increased thrombosis risk 1.

PNH

Chronic intravascular hemolysis: Persistent hemolysis with dark urine classically prominent in the morning, though this is not universal 3.
Thrombosis: High risk of venous thromboembolism, particularly in unusual sites (hepatic veins, portal vein, cerebral veins); thrombosis is a leading cause of death 7, 8, 9, 6.
Bone marrow failure: Cytopenias from associated aplastic anemia or marrow dysfunction 6, 3.
Smooth muscle dystonia: Esophageal spasm, abdominal pain, erectile dysfunction due to nitric oxide depletion from free hemoglobin 3.
Fatigue and dyspnea: From chronic anemia and hemolysis 4, 3.

Diagnostic Workup

PCH

Donath-Landsteiner test: The definitive diagnostic test; demonstrates biphasic hemolysin that binds at cold temperatures and causes hemolysis upon rewarming 1.
Direct antiglobulin test (DAT): Often negative or weakly positive 1.
Hemolysis markers: Elevated LDH, indirect bilirubin, decreased haptoglobin, increased free hemoglobin 10.
Flow cytometry: Not diagnostic for PCH but may reveal incidental PNH clones if both conditions coexist 1.

PNH

Flow cytometry: Essential diagnostic test detecting deficiency of GPI-anchored proteins (CD55, CD59) on granulocytes, monocytes, and red blood cells 10, 6.
Clone size quantification: Measure percentage of GPI-deficient cells; granulocyte clones >60% indicate markedly increased thrombosis risk 10.
Hemolysis panel: Elevated LDH, indirect bilirubin, decreased haptoglobin, increased free hemoglobin 10.
DAT: Negative (distinguishes from autoimmune hemolytic anemia) 10.
Bone marrow examination: Indicated when cytopenias suggest underlying marrow failure or MDS 10.

Specific Testing Indications for PNH

All patients with Budd-Chiari syndrome should be screened (9-19% prevalence) 9, 10.
Portal vein thrombosis patients warrant consideration (0-2% prevalence) 9, 10.
Aplastic anemia or bone marrow failure syndromes require PNH evaluation 10.
MDS workup should incorporate PNH testing 10.

Management

PCH

Supportive care: Avoid cold exposure, maintain warmth during hemolytic episodes 1.
Transfusion support: For severe anemia during acute episodes 1.
Self-limited course: Often resolves spontaneously, particularly in post-infectious cases 1.
No specific targeted therapy: Unlike PNH, there are no complement inhibitors specifically indicated for PCH 1.

PNH

Terminal complement (C5) inhibitors (first-line for hemolytic PNH):
- Eculizumab: IV every 2 weeks; first approved therapy, dramatically reduces thrombosis risk and improves survival 6, 4, 11.
- Ravulizumab: IV every 8 weeks; long-acting C5 inhibitor with 6-year durability data 11.
- Crovalimab: Subcutaneous every 4 weeks; newest FDA-approved C5 inhibitor 11.
Proximal complement inhibitors (for extravascular hemolysis):
- Pegcetacoplan: C3 inhibitor, subcutaneous twice weekly; addresses both intravascular and extravascular hemolysis 11.
- Iptacopan: Factor B inhibitor, oral twice daily; effective for both types of hemolysis 11.
- Danicopan: Factor D inhibitor, oral three times daily; used as add-on to C5 inhibitors 11.
Anticoagulation: Not routinely recommended on complement inhibitors due to dramatically reduced thrombosis risk 6.
Allogeneic hematopoietic stem cell transplantation: The only curative option; reserved for severe bone marrow failure refractory to immunosuppression or patients with SAA/PNH who fail IST 12, 6, 3.
Immunosuppressive therapy: For associated aplastic anemia component 12.

Key Clinical Pitfalls

Distinguishing PCH from PNH

Coexistence is possible: A patient can have both PCH (DL antibody-positive) and PNH clones simultaneously, making diagnosis challenging 1.
Flow cytometry in PCH: May reveal incidental PNH clones that are not clinically significant; the presence of DL antibody confirms PCH as the primary cause of hemolysis 1.
Clinical context matters: Cold-triggered episodic hemolysis suggests PCH; chronic hemolysis with thrombosis risk suggests PNH 1, 3.

PNH-Specific Considerations

Extravascular hemolysis on C5 inhibitors: Approximately 30% of patients develop clinically significant extravascular hemolysis despite C5 inhibition, requiring proximal complement inhibitors 11.
Breakthrough hemolysis: Can occur with any complement inhibitor during strong complement triggers (infection, surgery); may be more severe with alternative pathway inhibitor monotherapy 11.
Masked clones in bone marrow failure: Cytopenias from hypocellular marrow may mask PNH clone detection; flow cytometry remains essential 10.

Prognosis

PCH

Generally self-limited with good prognosis, particularly in post-infectious cases 1.
No increased mortality when managed supportively 1.

PNH

Historically life-threatening: High mortality from thrombosis before complement inhibitors 4, 3.
Transformed by complement inhibition: Survival now approaches that of healthy controls on C5 inhibitors 11, 3.
Ongoing morbidity: Chronic anemia, fatigue, and need for lifelong therapy remain challenges 6, 3.

How do paroxysmal cold hemoglobinuria (PCH) and paroxysmal nocturnal hemoglobinuria (PNH) differ in pathophysiology, clinical presentation, and management?

Have a follow-up question?